<DOC>
	<DOCNO>NCT00973219</DOCNO>
	<brief_summary>Rationale : Worldwide , approximately 400 million people chronically infect hepatitis B virus ( HBV ) . Chronic HBV infection increase risk develop cirrhosis , hepatic decompensation hepatocellular carcinoma ( HCC ) . The risk develop hepatocellular carcinoma high HBeAg positive patient high HBV DNA level , still relative risk remain 10 HBeAg negative patient . Furthermore show HBsAg clear cirrhosis developed , prognosis excellent . Recently investigator show HBeAg negative patient high HBV-DNA load low baseline HBsAg level significantly high HBsAg clearance ( positive predictive value 85 % ) combination therapy peginterferon alfa2a ( Peg-IFN ) adefovir . Based result , trial design investigate whether combination nucleos ( ) ide analogue combine PegIFN , could also provoke high rate HBsAg clearance chronic hepatitis B patient low ( HBV DNA &lt; 20,000 IU/mL ) viral load . Study design : This three arm open-label prospective randomize controlled trial . 150 patient enrol study assessment eligibility . All patient must document HBsAg positivity longer 6 month , HBeAg negativity , anti-HBe positivity , HBV DNA &lt; 20,000 IU/mL ALT &lt; 5 * upper limit normal . Patients Child Pugh class B C exclude . Group 1 consist patient treat Peg-IFN adefovir , group 2 consist patient treat Peg-IFN tenofovir group 3 consist untreated control . Patients group 1 2 receive medication period one year . For enrolment study liverbiopsy time enrolment compulsory advisable end treatment ( week 48 ) . Study population : The study population consist 150 patient chronically infect hepatitis B virus low viral load HBeAg negativity . Main study parameters/endpoints : The aim study investigate proportion HBeAg negative , inactive carrier hepatitis B virus low ( &lt; 20,000 IU/mL ) load lose HBsAg treat nucleot ( ) ide analogue/Peg-IFN combination therapy . In study investigator hypothesize treatment peg-interferon ADF Peg-IFN TDF HBeAg negative chronic hepatitis B patient low HBV DNA viral load induce high rate HBsAg loss , comparable patient high viral load treatment ADF Peg-IFN .</brief_summary>
	<brief_title>Hepatitis B Surface Antigen ( HBsAg ) Loss Chronic Hepatitis B Patients With Low Viral Load</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient &gt; 18 â‰¤ 70 year age Positive HBsAg 6 month . Negative HBeAg 6 month . HBV DNA &lt; 2.0 E04 IU/mL Serum ALT &lt; 5 * ULN determine two value take &gt; 14 day apart six month first dose study drug least one determination obtain screen period . Negative urine serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose test drug . Patients coinfected HCV , HIV decompensated liver disease , hepatocellular carcinoma , significant cardiac disease , significant renal disease , seizure disorder severe retinopathy . Patients receive nucleos ( ) ide analogues chronic hepatitis B within 6 week enrollment receive PegIFN within 3 month enrollment . Patients must receive systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) &lt; 3 month prior first dose study drug expectation treatment need time study . Positive test screen antiHAV IgM , antiHIV , HCV RNA . ( Patients clear hepatitis C virus include study ) Patients expect need systemic antiviral therapy provide study time participation study also exclude . Exception : patient limited ( &lt; 7 day ) course acyclovir herpetic lesion 1 month prior first administration test drug exclude . Evidence decompensated liver disease ( Child pugh BC ) Serum total bilirubin &gt; twice upper limit normal screen History evidence bleed esophageal varix condition consistent decompensated liver disease . History evidence medical condition associate chronic liver disease HBV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease include Wilson 's disease alfa1antitrypsin deficiency , alcoholic liver disease , toxin exposure , thalassemia ) . Women ongoing pregnancy breast feeding . Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 80,000 cells/mm3 screening . Hemoglobin &lt; 7.1 mmol/L ( &lt; 11.5 g/dL ) females &lt; 7.8 mmol/L ( &lt; 12.5 g/dL ) men screen . Serum creatinine level &gt; 1.5 time upper limit normal screening . Unstable ongoing severe psychiatric disease , especially depression ( stable patient include ) . History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis ) . History evidence chronic pulmonary cardiac disease associate functional limitation . Severe cardiac disease ( e.g. , NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) . History severe seizure disorder current anticonvulsant use clinically unstable disease . Evidence active suspect cancer history malignancy risk recurrence &gt; 20 % within 5 year . Patients lesion suspicious hepatic malignancy screen image study eligible likelihood carcinoma &lt; 10 % follow appropriate evaluation . Major organ transplantation . ( patient skin , cornea bone transplantation allow include study ) Thyroid disease thyroid function poorly control prescribed medication . Patients elevate thyroid stimulate hormone T4 concentration , elevation antibody thyroid peroxidase clinical manifestation thyroid disease stable prescribed medication exclude . Stable patient include . History evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) clinically relevant ophthalmological disorder due diabetes mellitus hypertension . Inability unwillingness provide inform consent abide requirement study . History evidence severe illness condition would make patient , opinion investigator , unsuitable study . Patients value alfafetoprotein &gt; 100 ng/mL exclude , unless stability ( le 10 % increase ) document least previous 3 month . Evidence current hard drug ( ) ( i.e . cannabis product allow ) and/or alcohol abuse ( 20g/day woman 30g/day men ) . Patients include another trial give investigational drug within 12 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HBsAg loss</keyword>
	<keyword>HBsAg seroconversion</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>low viral load</keyword>
	<keyword>inactive carrier hepatitis B</keyword>
</DOC>